NewAmsterdam Pharma gains from strong phase 3 obicetrapib results, LDL-C reduction and expansion into diabetes and ...
Tripadvisor shifts as Viator and TheFork lead growth with strong moats and a discounted valuation signaling major upside. See ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback